{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-029050","form_type":"8-K","ticker":"DMII","cik":"0002040475","company_name":"Drugs Made In America Acquisition II Corp.","filed_at":"2026-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.099623+00:00","generated_at":"2026-05-15T11:06:59.533266+00:00","sec_items":["1.01","8.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Drugs Made In America Acquisition II Corp. issues $150K convertible bridge note as part of $1.4M financing","bullets":["On March 11, 2026, Company issued a $150,000 unsecured convertible bridge note to Alpha Multi Family Office (Investor).","The bridge note is part of a larger $1,400,000 convertible notes financing under a Letter of Intent dated March 5, 2026 and an addendum dated March 9, 2026.","The note matures nine months from issuance, bears no interest, and is convertible at a 35% discount to market price upon a business combination.","The Company plans to use proceeds for accounting, audit, and other expenses related to the business combination.","The LOI originally contemplated $1,500,000 but was reduced to $1,400,000 after $100,000 in advisor fees."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-029050","json":"https://secwatch.observer/filing/0001213900-26-029050.json","markdown":"https://secwatch.observer/filing/0001213900-26-029050.md","text":"https://secwatch.observer/filing/0001213900-26-029050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2040475/000121390026029050/0001213900-26-029050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2040475/000121390026029050/ea0281959-8k_drugs2.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-15T11:06:59.533266+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"267b8676975fe9bb73cf18586014edcb01dafbde","claim":"Drugs Made In America Acquisition II Corp. incurred convertible notes of $150,000 with Alpha Multi Family Office at does not bear interest maturing nine months from the date of issuance.","evidence_excerpt":"On March 11, 2026, Drugs Made In America Acquisition II Corp. (the “ Company ”) issued an unsecured convertible note (the “ Bridge Note ”) to Alpha Multi Family Office (the “ Investor ”) in the principal amount of $150,000 (the “ Bridge Loan ”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/2040475/000121390026029050/0001213900-26-029050-index.htm","confidence":0.9},{"claim_id":"c7df68800c0a7f4159d71d5728d9a63f8c1256bd","claim":"Drugs Made In America Acquisition II Corp. entered into Bridge Note with Alpha Multi Family Office valued at $150,000 (effective 2026-03-11).","evidence_excerpt":"On March 11, 2026, Drugs Made In America Acquisition II Corp. (the “ Company ”) issued an unsecured convertible note (the “ Bridge Note ”) to Alpha Multi Family Office (the “ Investor ”) in the principal amount of $150,000 (the “ Bridge Loan ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2040475/000121390026029050/0001213900-26-029050-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001104659-26-057239","ticker":"BKNG","company_name":"Booking Holdings Inc.","filed_at":"2026-05-07T23:59:59+00:00","headline":"Booking Holdings issues $750M of 5.375% Senior Notes due 2036","event_type":"debt","sec_items":["1.01","2.03","8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03, 8.01, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-057239","json":"https://secwatch.observer/filing/0001104659-26-057239.json","markdown":"https://secwatch.observer/filing/0001104659-26-057239.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1075531/000110465926057239/0001104659-26-057239-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1075531/000110465926057239/tm2613920d1_8k.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On March 11, 2026, Drugs Made In America Acquisition II Corp. (the “ Company ”) issued an unsecured convertible note (the “ Bridge Note ”) to Alpha Multi Family Office (the “ Investor ”) in the principal amount of $150,000 (the “ Bridge Loan ”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2040475/000121390026029050/0001213900-26-029050-index.htm","comparable_excerpt":"in connection with the sale of $750,000,000 aggregate principal amount of the Company’s 5.375% Senior Notes due 2036","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1075531/000110465926057239/0001104659-26-057239-index.htm"}},{"accession":"0001993004-26-000044","ticker":"NWE","company_name":"NorthWestern Energy Group, Inc.","filed_at":"2026-06-02T11:22:44+00:00","headline":"NorthWestern Energy subsidiary enters $225M secured term loan, repays revolver","event_type":"debt","sec_items":["1.01","2.03","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001993004-26-000044","json":"https://secwatch.observer/filing/0001993004-26-000044.json","markdown":"https://secwatch.observer/filing/0001993004-26-000044.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1993004/000199300426000044/0001993004-26-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1993004/000199300426000044/nwe-20260527.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On March 11, 2026, Drugs Made In America Acquisition II Corp. (the “ Company ”) issued an unsecured convertible note (the “ Bridge Note ”) to Alpha Multi Family Office (the “ Investor ”) in the principal amount of $150,000 (the “ Bridge Loan ”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2040475/000121390026029050/0001213900-26-029050-index.htm","comparable_excerpt":"NW Corp's obligations under the Term Loan are secured by a $225 million first mortgage bond","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1993004/000199300426000044/0001993004-26-000044-index.htm"}},{"accession":"0001140361-26-023577","ticker":"TCPC","company_name":"BlackRock TCP Capital Corp.","filed_at":"2026-06-01T20:50:02+00:00","headline":"BlackRock TCP Capital closes $535.8M CLO securitization, repays existing debt facilities","event_type":"debt","sec_items":["1.01","1.02","2.03","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-023577","json":"https://secwatch.observer/filing/0001140361-26-023577.json","markdown":"https://secwatch.observer/filing/0001140361-26-023577.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370755/000114036126023577/0001140361-26-023577-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370755/000114036126023577/ef20075169_8k.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On March 11, 2026, Drugs Made In America Acquisition II Corp. (the “ Company ”) issued an unsecured convertible note (the “ Bridge Note ”) to Alpha Multi Family Office (the “ Investor ”) in the principal amount of $150,000 (the “ Bridge Loan ”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2040475/000121390026029050/0001213900-26-029050-index.htm","comparable_excerpt":"Item 1.01. Entry into a Material Definitive Agreement. On May 27, 2026 (the \" Closing Date \"), BlackRock TCP Capital Corp. (the \" Company \"), through its subsidiary, completed a $535,780,000 securitization of certain loans held by a subsidiary of the Company (the \" CLO Transaction \"). On the Closing Date and in connection with the CLO Transaction, BlackRock DLF 2026-C","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1370755/000114036126023577/0001140361-26-023577-index.htm"}},{"accession":"0000785161-26-000161","ticker":"EHC","company_name":"Encompass Health Corp","filed_at":"2026-06-01T20:26:16+00:00","headline":"Encompass Health issues $500M 5.875% notes due 2034; to redeem $400M of 4.500% notes due 2028","event_type":"debt","sec_items":["1.01","2.03","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000785161-26-000161","json":"https://secwatch.observer/filing/0000785161-26-000161.json","markdown":"https://secwatch.observer/filing/0000785161-26-000161.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/785161/000078516126000161/0000785161-26-000161-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/785161/000078516126000161/ehc-20260529.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On March 11, 2026, Drugs Made In America Acquisition II Corp. (the “ Company ”) issued an unsecured convertible note (the “ Bridge Note ”) to Alpha Multi Family Office (the “ Investor ”) in the principal amount of $150,000 (the “ Bridge Loan ”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2040475/000121390026029050/0001213900-26-029050-index.htm","comparable_excerpt":"On May 29, 2026, Encompass Health Corporation (the “Company”) completed the issuance and sale of $500 million in aggregate principal amount of its 5.875% Senior Notes due 2034 (the “Notes”), along with the related guarantees of the Notes by certain of the Company’s subsidiaries (the “Guarantees”), in a private offering.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/785161/000078516126000161/0000785161-26-000161-index.htm"}},{"accession":"0001628280-26-039479","ticker":"VVX","company_name":"V2X, Inc.","filed_at":"2026-06-01T20:10:20+00:00","headline":"V2X refinances $868.5M term loans with new tranche maturing 2030; SOFR+2% margin","event_type":"debt","sec_items":["1.01","2.03","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039479","json":"https://secwatch.observer/filing/0001628280-26-039479.json","markdown":"https://secwatch.observer/filing/0001628280-26-039479.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601548/000162828026039479/0001628280-26-039479-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601548/000162828026039479/vec-20260529.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On March 11, 2026, Drugs Made In America Acquisition II Corp. (the “ Company ”) issued an unsecured convertible note (the “ Bridge Note ”) to Alpha Multi Family Office (the “ Investor ”) in the principal amount of $150,000 (the “ Bridge Loan ”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2040475/000121390026029050/0001213900-26-029050-index.htm","comparable_excerpt":"The Amendment provides for, among other things, a new tranche of term loans under the Credit Agreement in an aggregate original principal amount of $868,522,978.38 (the “New Term Loans”), which New Term Loans replace or refinance in full all of the existing term loans outstanding under the Credit Agreement (as in effect immediately prior to the Amendment), as further set forth in the Amendment. The New Term Loans mature on December 6, 2030.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1601548/000162828026039479/0001628280-26-039479-index.htm"}},{"accession":"0001104659-26-068908","ticker":"PFG","company_name":"PRINCIPAL FINANCIAL GROUP INC","filed_at":"2026-06-01T20:05:54+00:00","headline":"Principal Financial Group issues $400M of 5.300% Senior Notes due 2037","event_type":"debt","sec_items":["1.01","2.03","8.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 2.03, 8.01, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068908","json":"https://secwatch.observer/filing/0001104659-26-068908.json","markdown":"https://secwatch.observer/filing/0001104659-26-068908.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1126328/000110465926068908/0001104659-26-068908-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1126328/000110465926068908/tm2614965d5_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 11, 2026, Drugs Made In America Acquisition II Corp. (the “ Company ”) issued an unsecured convertible note (the “ Bridge Note ”) to Alpha Multi Family Office (the “ Investor ”) in the principal amount of $150,000 (the “ Bridge Loan ”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2040475/000121390026029050/0001213900-26-029050-index.htm","comparable_excerpt":"On June 1, 2026, Principal Financial Group, Inc. (the “Company”) issued $400,000,000 aggregate principal amount of its 5.300% Senior Notes due 2037 (the “Notes”). The Notes were issued pursuant to the Senior Indenture, dated as of May 21, 2009 (the “Senior Indenture”), among the Company, as issuer, Principal Financial Services, Inc. (“PFSI”), as guarantor, and The Bank of New York Mellon Trust Company, N.A., as trustee, as supplemented by the Eighteenth Supplemental Indenture, dated as of June 1, 2026 (the “Supplemental Indenture”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1126328/000110465926068908/0001104659-26-068908-index.htm"}},{"accession":"0001213900-26-054183","ticker":"EMAT","company_name":"Evolution Metals & Technologies Corp.","filed_at":"2026-05-11T23:59:59+00:00","headline":"EMAT secures $100M convertible debenture facility from Yorkville; first $20M tranche issued","event_type":"debt","sec_items":["1.01","2.03","3.02","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-054183","json":"https://secwatch.observer/filing/0001213900-26-054183.json","markdown":"https://secwatch.observer/filing/0001213900-26-054183.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1866226/000121390026054183/0001213900-26-054183-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1866226/000121390026054183/ea0290073-8k_evolution.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On March 11, 2026, Drugs Made In America Acquisition II Corp. (the “ Company ”) issued an unsecured convertible note (the “ Bridge Note ”) to Alpha Multi Family Office (the “ Investor ”) in the principal amount of $150,000 (the “ Bridge Loan ”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2040475/000121390026029050/0001213900-26-029050-index.htm","comparable_excerpt":"The first Convertible Debenture (the “First Debenture”) in the principal amount of $20,000,000 was issued on May 7, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1866226/000121390026054183/0001213900-26-054183-index.htm"}},{"accession":"0000008947-26-000108","ticker":"AZZ","company_name":"AZZ INC","filed_at":"2026-05-08T23:59:59+00:00","headline":"AZZ refinances revolver; maturity extended to 2029, margins cut 50 bps","event_type":"debt","sec_items":["1.01","2.03","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: debt_financing, material_agreement","same SEC item: 1.01, 2.03, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000008947-26-000108","json":"https://secwatch.observer/filing/0000008947-26-000108.json","markdown":"https://secwatch.observer/filing/0000008947-26-000108.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/8947/000000894726000108/0000008947-26-000108-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/8947/000000894726000108/azz-20260507.htm"},"side_by_side_evidence":{"fact_type":"debt_financing","source_excerpt":"On March 11, 2026, Drugs Made In America Acquisition II Corp. (the “ Company ”) issued an unsecured convertible note (the “ Bridge Note ”) to Alpha Multi Family Office (the “ Investor ”) in the principal amount of $150,000 (the “ Bridge Loan ”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2040475/000121390026029050/0001213900-26-029050-index.htm","comparable_excerpt":"The Seventh Amendment (i) terminated the Initial Revolving Credit Commitments and simultaneously replaced them in their entirety with Extended Revolving Credit Commitments having a Maturity Date of May 7, 2029, (ii) decreased the interest rate margin applicable to the Revolving Credit Loans from margins ranging from 175 basis points to 275 basis points (subject to leverage ratio step-downs) to margins ranging from 125 basis points to 225 basis points (subject to leverage ratio step-downs)","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/8947/000000894726000108/0000008947-26-000108-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}